In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA(2A)R antagonists for the treatment of Parkinson's disease

Parkinson’s disease is considered the second most frequent neurodegenerative disease. It is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L-DOPA has been considered as the gold standard for treating Parkinson’s disease motor symptoms, however, due to the decrease...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulaamane, Yassir, Ibrahim, Mahmoud A. A., Britel, Mohammed Reda, Maurady, Amal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800045/
https://www.ncbi.nlm.nih.gov/pubmed/36112816
http://dx.doi.org/10.1515/jib-2021-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800045/
https://www.ncbi.nlm.nih.gov/pubmed/36112816
http://dx.doi.org/10.1515/jib-2021-0027

Ejemplares similares